Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Regulatory Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,289 |
Ending reported balance
After 2026-09-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Grant · Acquired 4,483 · Balance 20,708 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Row 2 · 2026-09-11 · Tax withholding · Disposed 2,419 · Balance 18,289 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 21:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 2,419 | $156.22 | $377,896.18 |
DisclosureSEC source: 0001965808-26-000015 · wk-form4_1789506243.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,289 F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 4,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000015 · wk-form4_1789506243.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,708 F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 20:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 4,367 | $0.00 Strike: $106.02 | $0.00 |
DisclosureSEC source: 0001965808-26-000013 · wk-form4_1783974461.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,367 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted February 1, 2021 and vested at 25% upon first anniversary (February 1, 2022) and remaining 75% vested in 36 equal monthly installments beginning on March 1, 2022. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 20:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 4,367 | $181.02 | $790,514.34 |
DisclosureSEC source: 0001965808-26-000013 · wk-form4_1783974461.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,225 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 20:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 4,367 | $106.02 | $462,989.34 |
DisclosureSEC source: 0001965808-26-000013 · wk-form4_1783974461.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2026 Filed Jul 9, 2026 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 8,433 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · derivative · entry 9 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,478 Underlying: Common Stock · 8,433 shares Expires 2033-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023. Read SEC document |
| July 09, 2026 Filed Jul 9, 2026 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 8,433 | $178.72 | $1,507,134.80 |
DisclosureSEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 6 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,225 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $179.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 09, 2026 Filed Jul 9, 2026 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 8,433 | $103.52 | $872,984.16 |
DisclosureSEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 5 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2026 Filed Jul 9, 2026 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 2,737 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · derivative · entry 8 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,911 Underlying: Common Stock · 2,737 shares Expires 2033-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023. Read SEC document |
| July 08, 2026 Filed Jul 9, 2026 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,737 | $178.54 | $488,672.19 |
DisclosureSEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 4 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,225 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 08, 2026 Filed Jul 9, 2026 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,737 | $103.52 | $283,334.24 |
DisclosureSEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 3,401 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · derivative · entry 7 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,648 Underlying: Common Stock · 3,401 shares Expires 2033-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,401 | $178.57 | $607,305.01 |
DisclosureSEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,225 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 22:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 3,401 | $103.52 | $352,071.52 |
DisclosureSEC source: 0001965808-26-000011 · wk-form4_1783636859.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 22:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 2,261 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001965808-26-000007 · wk-form4_1780437791.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,261 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 22:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,261 | $156.71 | $354,321.31 |
DisclosureSEC source: 0001965808-26-000007 · wk-form4_1780437791.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,225 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 22:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,261 | $79.02 | $178,664.22 |
DisclosureSEC source: 0001965808-26-000007 · wk-form4_1780437791.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 5,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 13 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,479 Underlying: Common Stock · 5,479 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 31,234 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 12 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,234 Underlying: Common Stock · 31,234 shares Expires 2036-02-13 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 11 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,359 Underlying: Common Stock · 1,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,358 shares on February 13, 2024, vested as to 1,358 shares on February 13, 2025, vested as to 1,359 shares on February 13, 2026, and will vest as to 1,359 shares on February 13, 2027, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,358 shares on February 13, 2024, vested as to 1,358 shares on February 13, 2025, vested as to 1,359 shares on February 13, 2026, and will vest as to 1,359 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 10 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,802 Underlying: Common Stock · 1,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 10,755 | $124.12 | $1,334,910.60 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 8 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,225 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 19,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 7 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,980 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 734 | $124.12 | $91,104.08 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 6 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,045 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 5 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 756 | $124.12 | $93,834.72 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 4 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,420 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 9 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,801 Underlying: Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 881 | $123.10 | $108,451.10 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,775 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestriced Stock Unit · Derivative | 801 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000003 · wk-form4_1770159888.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 800 shares on January 31, 2023, vested as to 800 shares on January 31, 2024, vested as to 801 shares on January 31, 2025, and vested as to 801 shares on January 31, 2026, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 800 shares on January 31, 2023, vested as to 800 shares on January 31, 2024, vested as to 801 shares on January 31, 2025, and vested as to 801 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 475 | $136.06 | $64,628.50 |
DisclosureSEC source: 0001965808-26-000003 · wk-form4_1770159888.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,056 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 801 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000003 · wk-form4_1770159888.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 457 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0000914475-25-000153 · wk-form4_1752268504.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,261 Underlying: Common Stock · 457 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 457 | $135.00 | $61,695.00 |
DisclosureSEC source: 0000914475-25-000153 · wk-form4_1752268504.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,730 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 457 | $79.02 | $36,112.14 |
DisclosureSEC source: 0000914475-25-000153 · wk-form4_1752268504.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,401 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000061 · wk-form4_1739574830.xml · derivative · entry 8 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,203 Underlying: Common Stock · 1,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, and will vest as to 1,401 shares on February 13, 2026, 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award. F9 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, and will vest as to 1,401 shares on February 13, 2026, 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,358 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000061 · wk-form4_1739574830.xml · derivative · entry 7 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,718 Underlying: Common Stock · 1,358 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F8 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,358 shares on February 13, 2024, vested as to 1,358 shares on February 13, 2025, and will vest as to 1,359 shares on February 13, 2026, and 1,359 shares on February 13, 2027, subject to the terms and conditions of the award. F8 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,358 shares on February 13, 2024, vested as to 1,358 shares on February 13, 2025, and will vest as to 1,359 shares on February 13, 2026, and 1,359 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 755 | $116.72 | $88,124.66 |
DisclosureSEC source: 0000914475-25-000061 · wk-form4_1739574830.xml · nonDerivative · entry 4 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,730 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,401 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000061 · wk-form4_1739574830.xml · nonDerivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 716 | $116.69 | $83,549.47 |
DisclosureSEC source: 0000914475-25-000061 · wk-form4_1739574830.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,084 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,358 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000061 · wk-form4_1739574830.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 6,401 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000061 · wk-form4_1739574830.xml · derivative · entry 6 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,401 Underlying: Common Stock · 6,401 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:13 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 34,153 | $0.00 Strike: $117.18 | $0.00 |
DisclosureSEC source: 0000914475-25-000061 · wk-form4_1739574830.xml · derivative · entry 5 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,153 Underlying: Common Stock · 34,153 shares Expires 2035-02-12 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000024 · wk-form4_1738709111.xml · derivative · entry 6 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 1, 2021. In accordance with the terms of the RSU, the award vested as to 1,180 shares on February 1, 2022, vested as to 1,179 shares on February 1, 2023, vested as to 1,179 shares on February 1, 2024, and vested as to 1,179 shares on February 1, 2025, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 1, 2021. In accordance with the terms of the RSU, the award vested as to 1,180 shares on February 1, 2022, vested as to 1,179 shares on February 1, 2023, vested as to 1,179 shares on February 1, 2024, and vested as to 1,179 shares on February 1, 2025, subject to the terms and conditions of the award. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 623 | $149.29 | $93,007.67 |
DisclosureSEC source: 0000914475-25-000024 · wk-form4_1738709111.xml · nonDerivative · entry 4 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,442 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000024 · wk-form4_1738709111.xml · nonDerivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestriced Stock Unit · Derivative | 801 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000024 · wk-form4_1738709111.xml · derivative · entry 5 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 801 Underlying: Common Stock · 801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 800 shares on January 31, 2023, vested as to 800 shares on January 31, 2024, vested as to 801 shares on January 31, 2025, and will vest as to 801 shares on January 31, 2026, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 800 shares on January 31, 2023, vested as to 800 shares on January 31, 2024, vested as to 801 shares on January 31, 2025, and will vest as to 801 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 422 | $153.05 | $64,586.72 |
DisclosureSEC source: 0000914475-25-000024 · wk-form4_1738709111.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,886 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.91 to $154.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 801 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000024 · wk-form4_1738709111.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.